# β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

> **NCT03123484** · PHASE2 · UNKNOWN · sponsor: **China Medical University, China** · enrollment: 80 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** β-elemene
- **DRUG:** EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)

## Key facts

- **NCT ID:** NCT03123484
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04
- **Primary completion:** 2019-04
- **Final completion:** 2019-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2017-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123484, "β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03123484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*